Your browser doesn't support javascript.
loading
Tobacco smoking and nicotine vaping in persons with first episode psychosis.
Bennett, Melanie E; Medoff, Deborah; Cowan, Tovah; Fang, Lijuan; Kacmarek, Corinne; Oikonomou, Maria Theodora; Calkins, Monica E; Baker, Krista K; Bencivengo, Donna; Boumaiz, Yasmine; Buchanan, Robert W; Campbell, Phillip; Chengappa, K N Roy; Conroy, Catherine G; Cooke, Akinyi; Dong, Fanghong; Fauble, Mandy; Goldberg, Richard W; Harvin, Alexander; Jumper, Megan B E; Kauffman, Belinda; Kelly, Christian; Kohler, Christian G; Kreyenbuhl, Julie; Li, Lan; Lucksted, Alicia; Margolis, Russell L; Marsteller, Jill A; Moxam, Alex; Namowicz, Denise; Oko, Jamie; Riggs, Jessie; Saravana, Arunadevi; Sarpal, Deepak K; Scheinberg, Rachel; Smith, William R; States, Richard; Taylor, Jerome; Vatza, Crystal; Wolcott, Max; Dickerson, Faith.
Afiliação
  • Bennett ME; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: mbennett@som.umaryland.edu.
  • Medoff D; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Cowan T; Department of Psychiatry, McGill University, Montreal, QC, Canada.
  • Fang L; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Kacmarek C; VA VISN5 Mental Illness Research, Education, and Clinical Center, Baltimore, MD, USA.
  • Oikonomou MT; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Calkins ME; Pennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, Univ
  • Baker KK; Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
  • Bencivengo D; Pennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, Univ
  • Boumaiz Y; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Buchanan RW; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Campbell P; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Chengappa KNR; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Conroy CG; Pennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, Univ
  • Cooke A; Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
  • Dong F; Pennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, Univ
  • Fauble M; University of Pittsburgh Medical Center, Western Behavioral Health at Safe Harbor, Erie, PA, USA.
  • Goldberg RW; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Harvin A; Department of Psychology, Sheppard Pratt, Baltimore, MD, USA.
  • Jumper MBE; Pennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, Univ
  • Kauffman B; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Kelly C; UPMC, Western Psychiatric Hospital, Pittsburgh, PA, USA.
  • Kohler CG; Pennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, Univ
  • Kreyenbuhl J; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Li L; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Lucksted A; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Margolis RL; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Marsteller JA; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Moxam A; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Namowicz D; Children's Services Center, Wilkes Barre, PA, USA.
  • Oko J; Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Riggs J; Pennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, Univ
  • Saravana A; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Sarpal DK; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; UPMC, Western Psychiatric Hospital, Pittsburgh, PA, USA.
  • Scheinberg R; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Smith WR; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • States R; University of Pittsburgh Medical Center, Western Behavioral Health at Safe Harbor, Erie, PA, USA.
  • Taylor J; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Vatza C; Pennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, Univ
  • Wolcott M; Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
  • Dickerson F; Department of Psychology, Sheppard Pratt, Baltimore, MD, USA.
Schizophr Res ; 267: 141-149, 2024 May.
Article em En | MEDLINE | ID: mdl-38547716
ABSTRACT
Tobacco smoking is highly prevalent in persons with psychosis and is the leading cause of preventable mortality in this population. Less is known about tobacco smoking in persons with first episode psychosis (FEP) and there have been no estimates about the prevalence of nicotine vaping in FEP. This study reports rates of tobacco smoking and nicotine vaping in young people with FEP enrolled in Coordinated Specialty Care programs in Pennsylvania and Maryland. Using data collected from 2021 to 2023, we examined lifetime and recent smoking and vaping and compared smokers and vapers to nonusers on symptoms, functioning, and substance use. The sample included 445 participants aged 13-35 with recent psychosis onset. Assessments were collected by program staff. Overall, 28 % of participants engaged in either smoking or vaping within 30 days of the admission assessment. Smokers and vapers were disproportionately male, cannabis users, and had lower negative symptom severity than non-smokers. Vapers had higher role and social functioning. Both smoking and vaping were related to a longer time from psychosis onset to program enrollment. We compare these findings to previous studies and suggest steps for addressing smoking and vaping in this vulnerable population.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Vaping Limite: Adolescent / Adult / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Vaping Limite: Adolescent / Adult / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article